These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893 [TBL] [Abstract][Full Text] [Related]
45. HPV vaccination in boys and men. Stanley M Hum Vaccin Immunother; 2014; 10(7):2109-11. PubMed ID: 25424825 [TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241 [TBL] [Abstract][Full Text] [Related]
47. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Broomall EM; Reynolds SM; Jacobson RM Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463 [TBL] [Abstract][Full Text] [Related]
48. USA dental health providers' role in HPV vaccine communication and HPV-OPC protection: a systematic review. Walker KK; Jackson RD; Sommariva S; Neelamegam M; Desch J Hum Vaccin Immunother; 2019; 15(7-8):1863-1869. PubMed ID: 30620632 [No Abstract] [Full Text] [Related]
49. Human papillomavirus, oropharyngeal cancer, and the latest vaccine: considerations for oral healthcare providers. Watt M; Li E; Closmann J; Chang O Gen Dent; 2024; 72(3):74-77. PubMed ID: 38640011 [TBL] [Abstract][Full Text] [Related]
51. Impact of prophylactic human papillomavirus vaccines on dermatology and venereology. Gross G G Ital Dermatol Venereol; 2008 Aug; 143(4):259-65. PubMed ID: 18833082 [TBL] [Abstract][Full Text] [Related]
52. [HPV vaccination and prevention of oropharyngeal cancers]. Del Pujol EM Rev Prat; 2022 Dec; 72(10):1078-1079. PubMed ID: 36891788 [No Abstract] [Full Text] [Related]
54. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829 [TBL] [Abstract][Full Text] [Related]
55. Beyond cervical cancer: burden of other HPV-related cancers among men and women. Chaturvedi AK J Adolesc Health; 2010 Apr; 46(4 Suppl):S20-6. PubMed ID: 20307840 [TBL] [Abstract][Full Text] [Related]
56. Equitable vaccination against human papillomavirus: the road ahead. Kanatas A; Mitchell DA Br J Oral Maxillofac Surg; 2018 Oct; 56(8):653-654. PubMed ID: 30107952 [No Abstract] [Full Text] [Related]
57. High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Baricevic I; He X; Chakrabarty B; Oliver AW; Bailey C; Summers J; Hampson L; Hampson I; Gilbert DC; Renehan AG Eur J Cancer; 2015 Apr; 51(6):776-85. PubMed ID: 25702585 [TBL] [Abstract][Full Text] [Related]
58. Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer. Whang SN; Filippova M; Duerksen-Hughes P Viruses; 2015 Sep; 7(9):5040-65. PubMed ID: 26393639 [TBL] [Abstract][Full Text] [Related]
59. Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men? Shum J; Kelsberg G; Safranek S J Fam Pract; 2015 Sep; 64(9):581-3. PubMed ID: 26546954 [TBL] [Abstract][Full Text] [Related]
60. Indications for the HPV vaccine in adolescents: a review of the literature. Soares GR; Vieira Rda R; Pellizzer EP; Miyahara GI J Infect Public Health; 2015; 8(2):105-16. PubMed ID: 25453595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]